Register Now - $40

DURATION:
1 Hour
CREDIT:
1 AMA PRA Category 1 Creditâ„¢, 1 Nursing Contact Hour (1 Pharmacologic Hour)

INSTRUCTORS:

Neal Rouzier, MD
Faculty Chairman

During this webinar, Dr. Rouzier will be reviewing additional literature that describes how serum levels do not predict symptom improvement in women.  He will review the different variables affecting the action of testosterone in women which are a result of intercellular metabolism and the sensitivity of the androgen receptor. In this webinar, he will describe the medical studies which support that testosterone administration is also neuro-protect as well as cardio-protective.

Objectives:

Upon completion of this workshop, the healthcare professional will be able to:

  1. Recall that in current AACE guidelines, testosterone is only recommended in women that have a diagnosis of HSDD.
  2. Review another paper in this series demonstrating that serum levels do not predict symptom improvement in women.
  3. Discuss the many papers that prove treatment should be guided clinically and not biochemically as levels and numbers are fraught with error.
  4. Review another important paper that should be given to each and every woman that is treated with testosterone.
  5. Recall that researchers suggest that in clinical practice, concentrations of testosterone in serum are somewhat arbitrary and should always be interpreted in accordance with the clinical presentation, i.e., symptomatic improvement matters; numbers do not.
  6. Demonstrate that evidence supports the short term efficacy and safety of high physiological doses of testosterone treatment.
  7. Describe the medical studies supporting that testosterone administration is neuro-protective and cardio-protective.
  8. Identify the different variables affecting the action of testosterone in an individual which are a result of intercellular metabolism and the sensitivity of the androgen receptor.